[go: up one dir, main page]

AU2001273215A1 - Olfactory neuron cultures and method of making and using the same - Google Patents

Olfactory neuron cultures and method of making and using the same

Info

Publication number
AU2001273215A1
AU2001273215A1 AU2001273215A AU7321501A AU2001273215A1 AU 2001273215 A1 AU2001273215 A1 AU 2001273215A1 AU 2001273215 A AU2001273215 A AU 2001273215A AU 7321501 A AU7321501 A AU 7321501A AU 2001273215 A1 AU2001273215 A1 AU 2001273215A1
Authority
AU
Australia
Prior art keywords
oxidative stress
subject
disease
alzheimer
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273215A
Other languages
English (en)
Inventor
Hossein A. Ghanbari
George Perry
Mark A Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Panacea Pharmaceuticals Inc
Original Assignee
Case Western Reserve University
Panacea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University, Panacea Pharmaceuticals Inc filed Critical Case Western Reserve University
Publication of AU2001273215A1 publication Critical patent/AU2001273215A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
AU2001273215A 2000-07-07 2001-07-06 Olfactory neuron cultures and method of making and using the same Abandoned AU2001273215A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21664800P 2000-07-07 2000-07-07
US60216648 2000-07-07
US21708700P 2000-07-10 2000-07-10
US60217087 2000-07-10
PCT/US2001/021380 WO2002004029A1 (fr) 2000-07-07 2001-07-06 Cultures de neurones olfactifs, procedes d'elaboration et d'utilisation

Publications (1)

Publication Number Publication Date
AU2001273215A1 true AU2001273215A1 (en) 2002-01-21

Family

ID=26911206

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273215A Abandoned AU2001273215A1 (en) 2000-07-07 2001-07-06 Olfactory neuron cultures and method of making and using the same

Country Status (6)

Country Link
US (3) US20020016284A1 (fr)
EP (1) EP1330267A4 (fr)
JP (1) JP2004502944A (fr)
AU (1) AU2001273215A1 (fr)
CA (1) CA2415084A1 (fr)
WO (1) WO2002004029A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080312128A1 (en) * 2005-04-29 2008-12-18 Edward Chaum Cellular Biomarker Antioxidant Assay and Uses Thereof
JP4940424B2 (ja) * 2005-10-07 2012-05-30 国立大学法人名古屋大学 神経細胞の酸化的損傷のマーカー及びその利用
WO2009152463A2 (fr) * 2008-06-12 2009-12-17 Genentech, Inc. Procédé de criblage pour identifier des composés qui inhibent la neurodégénérescence
US20120058099A1 (en) * 2009-03-04 2012-03-08 Children's Medical Center Corporation Use of hypoxanthine for promotion of neuronal outgrowth
EP2611929B1 (fr) 2010-09-01 2016-01-13 Promega Corporation Dosage de glutathion oxydé
KR101302173B1 (ko) 2012-12-07 2013-08-30 이화여자대학교 산학협력단 Ｈｍｏｘ１ 유전자의 메틸화 변화를 이용한 알츠하이머 질환의 진단용 조성물 및 이를 이용한 알츠하이머 질환의 진단방법
JP6326413B2 (ja) * 2013-07-05 2018-05-16 株式会社ヤクルト本社 ペントシジン生成阻害剤
WO2020039732A1 (fr) * 2018-08-24 2020-02-27 住友化学株式会社 Agrégation de cellules comprenant un neurone olfactif ou une cellule précurseur de celui-ci, et son procédé de production
JP7607149B2 (ja) * 2021-04-09 2024-12-26 カチョン ユニバーシティ オブ インダストリー－アカデミック コーオペレイション ファウンデイション グリコトキシン、グリコトキシンに結合した特定タンパク質、またはグリコトキシン－特定タンパク質複合体を含む神経変性疾患のバイオマーカー

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869266A (en) * 1990-03-06 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Human olfactory neuron cultures to diagnose Alzheimer's disease
JP3759620B2 (ja) * 1996-04-18 2006-03-29 メディカル リサーチ カウンシル 平滑筋細胞における酸化代謝：それに関する方法と物質
US20030211622A1 (en) * 1998-06-29 2003-11-13 Roberts L. Jackson Methods and compositions to assess oxidative brain injury

Also Published As

Publication number Publication date
JP2004502944A (ja) 2004-01-29
US20040146946A1 (en) 2004-07-29
CA2415084A1 (fr) 2002-01-17
WO2002004029A1 (fr) 2002-01-17
US20040146945A1 (en) 2004-07-29
US20020016284A1 (en) 2002-02-07
EP1330267A1 (fr) 2003-07-30
EP1330267A4 (fr) 2005-10-12

Similar Documents

Publication Publication Date Title
Liu et al. Autophagy and protein aggregation after brain ischemia
Yamashima et al. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA‐074: a novel strategy for neuroprotection based on ‘calpain–cathepsin hypothesis’
Fernandez-Vizarra et al. Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease
Montine et al. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype
Browne et al. Oxidative stress in Huntington's disease
Moreira et al. Effect of amyloid β‐peptide on permeability transition pore: A comparative study
Hall et al. Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils
Matsuyama et al. Hypothesis: microtubules, a key to Alzheimer disease.
Mattson et al. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein
Gasparini et al. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells
Cummings et al. Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease
Parpura-Gill et al. The inhibitory effects of β-amyloid on glutamate and glucose uptakes by cultured astrocytes
Kim et al. Immunocytochemical evidence that amyloid β (1–42) impairs endogenous antioxidant systems in vivo
EP0655247B1 (fr) Utilisation de la vincristine pour l'évaluation de substances au niveau neuronal
Dawbarn et al. Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type
Luo et al. Estrogen deficiency exacerbates learning and memory deficits associated with glucose metabolism disorder in APP/PS1 double transgenic female mice
Bu et al. Nerve growth factor induces rapid increases in functional cell surface low density lipoprotein receptor-related protein
Benzing et al. Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to tau and PHF in Alzheimer's disease
US20020016284A1 (en) Olfactory neuron cultures and method of making and using the same
Choi et al. Anti-apoptotic proteins are oxidized by Aβ25–35 in Alzheimer's fibroblasts
US20100297761A1 (en) Novel Use of Liver X Receptor Agonists
Rodríguez‐Puertas et al. 125I‐galanin binding sites in Alzheimer's disease: Increases in hippocampal subfields and a decrease in the caudate nucleus
Yoneyama et al. In vivo depletion of endogenous glutathione facilitates trimethyltin-induced neuronal damage in the dentate gyrus of mice by enhancing oxidative stress
JP2002508834A (ja) βアミロイドを減少させる薬剤を同定する方法
Paine et al. Immunoreactivity to Lys63-linked polyubiquitin is a feature of neurodegeneration

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application